Overcoming Barriers to Optimal Treatment and Management of FLT3-Mutated AML in the Frontline Setting

Intended Audience: Hematologists/oncologists and their teams of NPs, PAs, nurses, and pharmacists caring for patients with AML

Are you up to date on the latest evidence in FLT3-mutated AML? Challenge yourself with this AdaptiveMedEd activity exploring cutting-edge evidence on new developments in the management of FLT3-mutated AML.

Customized learning pathways based on the speed and accuracy of your answers will provide you with real-time feedback and resources targeted to your level of knowledge. This curated education covers outcomes from clinical trials, recent guideline updates, and insights on timely testing for FLT3 mutation and incorporating FLT3 inhibitors into frontline treatment plans. Upon completion, you will receive a personalized downloadable resource with all of the information presented to you during the activity.

• Apply evidence-based guidelines and expert strategies to guide timely molecular testing and monitoring throughout the AML care continuum
  
  
• Appraise the most up-to-date clinical trial data on current and emerging FLT3 inhibitors for newly diagnosed, FLT3-mutated AML

• 0.25 CME/CE for Physicians (ACCME)
• 0.25 CME/CE for Physician Assistants (AAPA)
• 0.25 CH/CE for Nurse Practitioners (AANP)
• 0.25 CPE for Pharmacists (ACPE + NABP)
• 0.25 CNE for Nurses (ANCC)

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Daiichi Sankyo, Inc.